Assessing human papillomavirus vaccine efficacy and safety

Journal of the American Osteopathic Association

Volumn 108, Issue 4 SUPPL 2, 2008, Pages

  Hendrix, Susan L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CAPSID PROTEIN; CAPSID PROTEIN L1; HEPATITIS A VACCINE; PLACEBO; WART VIRUS VACCINE;

AGE DISTRIBUTION; ANUS CANCER; ARTHRALGIA; BODY TEMPERATURE; CANCER IMMUNIZATION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT CANCER; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MULTIPLE CYCLE TREATMENT; MYALGIA; PAIN; PAPILLOMATOSIS; PENIS CANCER; RASH; RECURRENT INFECTION; RECURRENT RESPIRATORY PAPILLOMATOSIS; RESPIRATORY TRACT INFECTION; SCREENING; SHORT SURVEY; SIDE EFFECT; URTICARIA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VAGINA CANCER; VIRUS CARCINOGENESIS; VIRUS CARRIER; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS;

FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 44849141109     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (8)

1. Okonek BAM, Morganstein, eds. Development of polio vaccines. In: Access Excellence Classic Collection. Available at: http://www.accessexcellence.org/AE/ AEC/CC/polio.html. Accessed March 30, 2008.
2. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr. 2003;31:111-116.
3. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler DM, et al: HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial [published correction appears in Lancet. 370:1414]. Lancet. 2007;369:2161-2170.
4. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE I) investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943.
5. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356:1915-1927.
6. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al; for the Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
7. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
8. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.